Maolei Zhang
Overview
Explore the profile of Maolei Zhang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
2029
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen J, Gao Y, Zhong J, Wu X, Leng Z, Liu M, et al.
Cell Rep Med
. 2025 Feb;
:101993.
PMID: 39952237
No abstract available.
2.
Chen J, Gao Y, Zhong J, Wu X, Leng Z, Liu M, et al.
Cell Rep Med
. 2024 Oct;
5(11):101806.
PMID: 39481387
The immunosuppressive tumor microenvironment (TME) is a prominent feature of glioblastoma (GBM), the most lethal primary brain cancer resistant to current immunotherapies. The mechanisms underlying GBM-TME remain to be explored....
3.
Li F, Yang K, Gao X, Zhang M, Gu D, Wu X, et al.
Sci Transl Med
. 2024 Oct;
16(767):eadk9524.
PMID: 39356747
MYC promotes tumor growth through multiple mechanisms. Here, we show that, in human glioblastomas, the variant transcript encodes a 114-amino acid peptide, MYC pre-mRNA encoded protein (MPEP), from the upstream...
4.
Hu Z, Yang L, Zhang M, Tang H, Huang Y, Su Y, et al.
Cell Metab
. 2024 May;
36(7):1586-1597.e7.
PMID: 38703762
The mitochondrial genome transcribes 13 mRNAs coding for well-known proteins essential for oxidative phosphorylation. We demonstrate here that cytochrome b (CYTB), the only mitochondrial-DNA-encoded transcript among complex III, also encodes...
5.
Zhong J, Wu X, Gao Y, Chen J, Zhang M, Zhou H, et al.
Nat Commun
. 2023 Jul;
14(1):4467.
PMID: 37491377
Activated by its single ligand, hepatocyte growth factor (HGF), the receptor tyrosine kinase MET is pivotal in promoting glioblastoma (GBM) stem cell self-renewal, invasiveness and tumorigenicity. Nevertheless, HGF/MET-targeted therapy has...
6.
Cheng R, Li F, Zhang M, Xia X, Wu J, Gao X, et al.
Cell Res
. 2022 Oct;
33(1):30-45.
PMID: 36241718
Mutations of the RAS oncogene are found in around 30% of all human cancers yet direct targeting of RAS is still considered clinically impractical except for the KRAS mutant. Here...
7.
Zhong J, Yang X, Chen J, He K, Gao X, Wu X, et al.
Nat Commun
. 2022 Aug;
13(1):4795.
PMID: 35970825
Glioblastoma (GBM) is a highly aggressive primary brain tumour and is resistant to nearly all available treatments, including natural killer (NK) cell immunotherapy. However, the factors mediating NK cell evasion...
8.
Xia X, Li X, Li F, Wu X, Zhang M, Zhou H, et al.
Mol Cancer
. 2022 Jun;
21(1):124.
PMID: 35672742
No abstract available.
9.
Gao X, Xia X, Li F, Zhang M, Zhou H, Wu X, et al.
Nat Cell Biol
. 2021 Mar;
23(3):278-291.
PMID: 33664496
Activated EGFR signalling drives tumorigenicity in 50% of glioblastoma (GBM). However, EGFR-targeting therapy has proven ineffective in treating patients with GBM, indicating that there is redundant EGFR activation. Circular RNAs...
10.
Huang N, Li F, Zhang M, Zhou H, Chen Z, Ma X, et al.
Cell Metab
. 2021 Feb;
33(2):454.
PMID: 33535099
No abstract available.